GeoVax Labs, Inc. Appoints Arban Domi as Director, Vector Development
November 22, 2013 at 07:05 am
Share
GeoVax Labs, Inc. announced the appointment of Arban Domi, Ph.D., as its Director, Vector Development. Dr. Domi will not only be a key player in the continued development of GeoVax's HIV vaccines currently being evaluated in human clinical trials, but also in the development of versions of the Company's vaccines for the subtypes of HIV affecting the developing world. Dr. Domi's experience will also be instrumental in the company's evaluation of the suitability of vaccine constructs for commercial-scale vaccine manufacturing processes.
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using proprietary platforms. Its product pipeline includes ongoing human clinical trials for a Covid-19 vaccine and a gene-directed therapy against advanced head and neck cancers. Its additional research and development programs include preventive vaccines against Mpox and smallpox, hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan and Marburg), Zika virus and malaria, as well as immunotherapies for multiple solid tumors. The Companyâs portfolio of wholly owned, co-owned, and in-licensed intellectual property, stands at over 155 granted or pending patent applications spread over 24 patent families. Its product candidate includes GEO-CM04S1, GEO-CM02, Gedeptin, MVA-VLP-MUC1, GEO-ZM02 and others. Its lead infectious disease candidate is GEO-CM04S1, a COVID-19 vaccine targeting high-risk immunocompromised patient populations.